|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date12 Sep 2013 |
Phase III study combined with post-marketing clinical study of RM1319 in patients with inborn errors of bile acid metabolism, including children
/ CompletedNot Applicable Acceptability study of a new paediatric formulation of Orphacol® (cholic acid) in paediatric patients treated for inborn errors in primary bile acid synthesis due to 3ß-Hydroxy-?5-C27- steroid oxidoreductase deficiency or ?4-3-Oxosteroid-5ß-reductase deficiency. - ORPH-PAED-01
100 Clinical Results associated with Laboratoires C.T.R.S. SAS
0 Patents (Medical) associated with Laboratoires C.T.R.S. SAS
01 Apr 2014·Medecine sciences : M/SQ4 · MEDICINE
Q4 · MEDICINE
Article
Author: Duguet, Christophe ; Ferry, Antoine
100 Deals associated with Laboratoires C.T.R.S. SAS
100 Translational Medicine associated with Laboratoires C.T.R.S. SAS